rifampicin sandoz 300,300 mg capsules
central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - rifampicin - hard capsule - rifampicin 300 mg - antimycobacterials
rimstar 4-fdc rifampicin 150mg / isoniazid 75mg film-coated tablet
sandoz private limited sandoz house, dr.annie besant road, worli, - rifampicin isoniazid pyrazinamide ethambutol - film-coated tablet - rifampicin 150mg isoniazid 75mg pyrazinamide - antimycobacterials: combinations of drugs for
rifampicin capsules
rifampicin - capsule - 150mg - rifampicin
rifampicin isoniazid tablets film-coated
lupin limited - rifampicin, isoniazid - tablets film-coated - 150mg+ 75mg
rifampicin isoniazid pyrazinamide tablets
lupin limited - rifampicin, isoniazid, pyrazinamide - tablets - 60mg+ 30mg+ 150mg
rifampicin isoniazid pyrazinamide ethambutol hydrochloride tablets film-coated
lupin limited - rifampicin, isoniazid, pyrazinamide, ethambutol (ethambutol hydrochloride) - tablets film-coated - 150mg+ 75mg+ 400mg+ 275mg
rifampicin 60mg-isoniazid 30mg tablets tablets dispersible
lupin limited - rifampicin, isoniazid - tablets dispersible - 60mg+ 30mg
rimycin 300 rifampicin 300 mg capsule bottle
alphapharm pty ltd - rifampicin, quantity: 300 mg - capsule, hard - excipient ingredients: purified talc; gelatin; purified water; ascorbic acid; magnesium stearate; brilliant blue fcf; colloidal anhydrous silica; sodium lauryl sulfate; titanium dioxide; erythrosine; lactose monohydrate - indications as at 5 december 2001 : tuberculosis. in the initial treatment and in retreatment of patients with tuberculosis, rifampicin must be used in conjunction with at least one other antituberculosis drug. leprosy - in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the non-infectious state which may be expected to occur in three to four months of treatment. - as an alternative drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other anti-leprosy drugs. - as an alternative drug in all those patients having true drug allergy to the more commonly used anti-leprosy drugs.,meningococcal disease prophylaxis of meningococcal disease in close contacts of known cases and in carriers (rifampicin is not indicated for the treatment of meningococcal infections).,haemophilus influenzae prophylaxis of household contacts of patients with haemophilus influenzae type b.,buruli ulcer for the treatment of myc
rimycin 150 rifampicin 150 mg capsule bottle
alphapharm pty ltd - rifampicin, quantity: 150 mg - capsule, hard - excipient ingredients: ascorbic acid; magnesium stearate; iron oxide red; colloidal anhydrous silica; purified water; lactose monohydrate; brilliant blue fcf; purified talc; iron oxide yellow; erythrosine; gelatin; sodium lauryl sulfate; titanium dioxide - indications as at 5 december 2001 : tuberculosis. in the initial treatment and in retreatment of patients with tuberculosis, rifampicin must be used in conjunction with at least one other antituberculosis drug. leprosy - in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the non-infectious state which may be expected to occur in three to four months of treatment. - as an alternative drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other anti-leprosy drugs. - as an alternative drug in all those patients having true drug allergy to the more commonly used anti-leprosy drugs.,meningococcal disease prophylaxis of meningococcal disease in close contacts of known cases and in carriers (rifampicin is not indicated for the treatment of meningococcal infections).,haemophilus influenzae prophylaxis of household contacts of patients with haemophilus influenzae type b.,buruli ulcer for the treatment of myc
royce rifampicin capsule 150mg
goldplus universal pte ltd - rifampicin - capsule - rifampicin 150mg